



# Marius Jack Coetzee

- Affiliated Associate Professor: Department of Haematology and Cell Biology, School of Pathology, University of the Free State, Bloemfontein, South Africa.
- Clinical Haematologist, Academic Group Practice, Universitas Private Hospital, Bloemfontein

## PROFILE



Bloemfontein, 9301



+27 (0) 82 550 1968



mjcoetzee@gmail.com  
coetzeemj@ufs.ac.za



25 May 1955



Male



White



South African Citizen



English, Afrikaans, German  
(basic), South Sotho & Zulu  
(rudimentary)



<https://orcid.org/0000-0003-2762-0966>

## Professional Registrations

Health Professions Council of SA (HPCSA):

- Pathologist (Haematological) with the subspecialty of Clinical Haematology

General Medical Council (GMC) (UK)

- Medical practitioner

## Qualifications

- *MBChB*  
University of Pretoria  
1979
- *Diploma in Tropical Medicine and Hygiene (DTM&H)*  
University of Witwatersrand  
1986
- *Master of Medicine (Haematology)* [MMed(Path)]  
University of Pretoria  
1987
- *Fellow of the Faculty (now College) of Pathologists of South Africa (Haem)* [FFPath(SA) Haem]  
1987
- *Short learning programme on the assessment of learning in higher education (NQF 7).*  
University of the Free State  
2007
- *Effective People Management: Short course*  
University of Cape Town Business School  
2012
- *Qualifi Level 5 Certificate in Teaching English as a Foreign Language*  
The TEFL Academy  
2020
- *Teaching Business English Course*  
The TEFL Academy  
2020
- *UCT Copy-editing online short course*  
University of Cape Town, presented in collaboration with online education company, GetSmarter  
November 2020
- *Publons Academy Practical Peer Review course*  
Publons Academy <https://publons.com/about/home/>  
January 2021
- *Cochrane Online Protocol Development Course*  
Cochrane South Africa and SAMRC  
June 2021

### **SKILLS**

- Bleeding disorders
- Clinical trials
- Editing
- Haematological pathology
- Patient Blood Management
- Undergraduate and postgraduate Medical Teaching & Research
- Teaching English as a Foreign/Second Language

### **Work Experience**

- 1980-1983: Intern in Baragwaneth Hospital and medical officer in various hospitals in South Africa
- 1983-1987: Pathology Registrar: Pretoria Academic Hospital & University of Pretoria
- 1988-1999: MRC Fellowship: Dept. of Human Genetics, Univ. of the Witwatersrand, Johannesburg
- 1990-July 2008: Senior Pathologist/Senior Lecturer Dept. of Haematology & Cell Biology, UFS
- August 2009-October 2009: Acting Head Dept. of Haematology & Cell Biology
- 2010-2014: Deputy chair of the NHLS Haematology Expert Committee
- July 2014-June 2016: Pathology Representative of the Universitas Academic Business Unit
- October-December 2016: Acting Head of the Department of Chemical Pathology, UFS and Universitas NHLS
- 2015-2018: Chair of the NHLS Haematology Expert Committee
- July 2017-: Member of the Health Sciences Research Ethics Committee, UFS
- November 2009-May 2020: Associate Professor and Head of Department of Haematology & Cell Biology
- June 2020-: Affiliated Associate Professor, Department of Haematology & Cell Biology, UFS
- September 2020-: Limited private practice, Academic Group Practice, Universitas Private Hospital, Bloemfontein

### **Teaching Activities**

- 1990-: Various MBChB lecture series on haematology and immunology
- 2000-2013: Module leader of MEQ264 (MHAE2724) (Haematology and Immunology) in MBChB
- 1990-: Postgraduate MMed(Haem) registrar training
- MPhil (Clinical Haematology)

### **Examiner**

- Haematology postgraduate examinations:
  - College of Pathologists of South Africa: FCPATH(SA) Haematology and Clinical Pathology, and Certificate of Clinical Haematology(SA) Paed, Phys and Path
  - MMed(Haematology) at SMU, University of Stellenbosch, University of Pretoria
- External examiner of various MMed research reports (Universities of Pretoria, Witwatersrand, UKZN, SMU, UCT)
- External examiner of various MSc theses (UKZN, University of the North West, Wits)
- 2009 November: External examiner College of Medicine, University of Malawi.

## **Reviewer**

### **International**

- British Journal of Haematology
- International Journal of Laboratory Haematology
- Journal of Clinical Pathology
- Orphanet Journal of Rare Diseases
- Turkish Journal of Hematology

### **South African**

- Health SA
- Journal of Medical Laboratory Science and Technology SA (continued from Medical Technology SA)
- South African Medical Journal

## **Membership of professional and other bodies**

- SA Haemophilia Foundation of South Africa, Medical and Scientific Advisory Council (MASAC)
- The Federation of South African Societies of Pathology (FSASP) - Congress convener 1995
- The South African Society for Haematology (SASH): Chairman of the Clinical Haematology Subcommittee President September 2009 to November 2010.
- College of Medicine of South Africa - was heavily involved in committees (helped with establishing the examinations for the Certificate in Clinical Haematology and the FCPATH in haematology).
- Associate of the Royal College of Pathologists.
- Membership of the International Society on Thrombosis and Haemostasis.
- Member of the South African Medical Association
- Member of the World Federation of Hemophilia
- Member of the Society for the Advancement of Blood Management (USA) (2018-2020)
- Member of the Foundation for Women and Girls with Blood Disorders (FWGBD) (2020-)

## **Courses attended and official visits**

- Blood transfusion for registrars, November-December 1987, Western Province Blood Transfusion Service, Cape Town
- Blood transfusion for MRCPATH, London, April 1988
- Haematological morphology for MRCPATH, St Mary's Medical School, London, May 1988
- Van Creveld Haemophilia Clinic, Utrecht Medical University Centre, Netherlands, February 2003
- Visit to the Medical College, University of Malawi – curriculum review and co-operation, 2007

### **Awards**

- Anglo-American Undergraduate Scholarship: 1974-1979
- South African Medical Research Council Post-Specialisation Fellowship at the Department of Human Genetics, University of the Witwatersrand: 1988–1989
- World Federation of Haemophilia Training Fellowship to the Van Creveld Haemophilia Clinic, Utrecht Medical University Centre, Netherlands, February 2003

### **Research interests**

- Haemophilia and bleeding disorders
- Hereditary haemorrhagic telangiectasia (NHLS Trust funding)
- Patient Blood Management
- Clinical Haematology

### **Congress presentations**

- Federation of South African Societies of Pathology annual Congresses, South Africa
- World Federation of Hemophilia Congresses
- International Society of Hematology Congresses
- Pathred (NHLS), South Africa

## Publications

Pubmed CV available at <https://www.ncbi.nlm.nih.gov/myncbi/marius.coetzee.1/bibliography/public/>

1. Truter PJ, Franzen S, Van Der Merwe JV, Coetzee MJ: Premature closure of the ductus arteriosus causing intra-uterine death. *S Afr Med J* 1986;70:557-558.
2. Coetzee MJ, Bartleet SC, Ramsay M, Jenkins T. Glucose-6-phosphate dehydrogenase (G6PD) electrophoretic variants and the *PvuII* polymorphism in southern African populations. *Human Genetics* 1992;98:111-114.
3. Coetzee MJ, Badenhorst PN, De Wet JI, Joubert G. Haematological condition of the San (Bushmen) relocated from Namibia to South Africa. *S Afr Med J* 1994; 84:416-420.
4. Emmerich J, Chadeuf G, Coetzee MJ, Alhenc-Gelas M, Fiessinger J-N, Aiach M. A phenylalanine 402 to leucine mutation is responsible for a stable inactive conformation of antithrombin. *Thrombosis Research* 1994; 76:307-315.
5. Coetzee MJ, Stassen AF, Joubert G, Barnard HC. The haematological condition of the San (Bushmen) relocated to Schmidtsdrif: a three-year follow-up study. *S Afr J Food Science and Nutrition* 1996; 8:44-48.
6. Coetzee MJ, Gordeuk VR, Barnard HC, Joubert G, Stassen AF. Iron overload in a Venda community: a pilot study. *S Afr J Food Science and Nutrition* 1996; 8:114-115.
7. Coetzee MJ, Shuttleworth MHG, Kaschula ROC. How to be the honorary secretary of a medical society in South Africa. *Geneeskunde – The Medical Journal* 1996; 38:28-32.
8. Coetzee MJ, Boshoff B, Goedhals L, Pienaar FD. Formula C: a popular, cheap and readily available relief for radiation and cancer chemotherapy mucositis. *S Afr Med J* 1997; 87:80-81.
9. Coetzee MJ, Gordeuk VR, De Kock A, Barnard HC, Joubert G, Stassen AF. Human leucocyte antigen (HLA) frequencies in rural Venda. *S Afr Med J* 1997; 87:183-184.
10. De Kock A, Heyns du P, Badenhorst PN, Coetzee MJ. Human leucocyte antigen frequencies of the Free State population, South Africa. *South African Journal of Science* 1997; 93:335-337.
11. Oberholzer MA, Nel L, Fourie MC, Coetzee MJ. A comparison between the Sedimatic system and the Westergren method of determining erythrocyte sedimentation rate. *Medical Technology SA* 1998; 12(1):257-258.
12. Coetzee MJ, Badenhorst PN, Le Roux EP, Doman MJ. Haematology outreach clinics in the Free State and Northern Cape. *S Afr Med J* 1998; 88(6):702-706.
13. van Wyk V, Coetzee MJ, Alexander KC, Badenhorst PN. Haemostatic profile of the San (Bushmen) relocated to Schmidtsdrif. *S Afr Med J*. 1998 Jun;88(6):715-6.
14. Vosloo WM, Coetzee MJ, Pretorius GHJ. Haemophilia A carrier detection in the Free State and Northern Cape. *S Afr Med J* 1999; 89:625-626.
15. Coetzee MJ, Writes R, Van Zyl M, Ferreira C, Pieters H, Münster M. Evaluation of a WHO colour scale for detection of anaemia in a haematology clinic. *S Afr Med J* 2000; 90:489.
16. Djordjevic Z, Coetzee MJ, Badenhorst PN, Nel M, Joubert G. An audit of a walk-in anticoagulation clinic that uses near-patient testing. *S Afr Med J* 2000;90(7):706-707
17. Davies WR, Hepburn DP, Coetzee MJ, Badenhorst PN, Goedhals L, Nel M. Patient satisfaction at haematology and oncology clinics in the Free State and Northern Cape. *Curationis* 2002; 25(2):63-68.
18. Coetzee MJ. The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia. *Haemophilia* July 2007;13(4): 443-444.
19. Coetzee MJ. Pagophagia when ice is not available – drink cold water. *S Afr Med J* April 2008; 98(4):232
20. Alli A, Coetzee M, Louw V, Van Rensburg B, Rossouw G, Thompson L, Thein SL. Sick cell disease in a carrier with pyruvate kinase deficiency. *Hematology* 2008;13(6):369-372.
21. Coetzee MJ, Louw VJ, Gartrell K, Viljoen CD. Chakalaka-induced vasodilatation in patients with chronic myeloid leukaemia on tyrosine kinase inhibitors. *S Afr Med J* 2009;99(12):870-871
22. Coetzee MJ. Clinical haematology training in South Africa. *S Afr Med J* 2010;100(9):544-545.
23. Coetzee MJ. Inappropriate delegation. *United Kingdom Casebook* 2011;19(2):24. (published by the Medical Protection Society ISSN 1366 4409. Available on [www.medicalprotection.org](http://www.medicalprotection.org))



24. Mahlangu JN, Coetzee MJ, Laffan M, Windyga J, Yee TT, Schroeder J, Haaning J, Siegel JE and Lemm G. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIIa variant BAY 86-6150 in hemophilia. *Journal of Thrombosis and Haemostasis* 2012;10(5): 773–780.
25. Alli NA, Patel M, Alli HD, Bassa F, Coetzee MJ, Davidson A, Essop MR, Lakha A, Louw VJ, Novitzky N, Philip V, Poole JE, Wainwright R. Recommendations for the management of sickle cell disease in South Africa. *S Afr Med J* 2014;104(11): 743-751.
26. Coetzee M, Joubert J. Helpful hints for writing SI units. *S Afr Med J* 2015;105:80.
27. Coetzee M. Honesty is the best policy. *Junior Doctor*. 2016;6(1):15. (published by the Medical Protection Society ISSN 1366 4409. Available on [www.medicalprotection.org](http://www.medicalprotection.org))
28. Weyers R, Coetzee MJ, Nel M. Iron status determination in pregnancy using the Thomas plot. *International Journal of Laboratory Hematology*. 2016;38(2):119-24.
29. Coetzee MJ, Blumberg LH, Paweska JT, Leman P, Swanepoel R, de Kock A. Crimean-Congo haemorrhagic fever presenting with undiagnosed chronic myeloid leukaemia. *Southern African Journal of Infectious Diseases* 2017;32:142-4.
30. Coetzee MJ, Joubert G, Swart M, Streicher A, Kruger M, Koekemoer H. An audit of the completion of bone marrow specimen request forms at an academic laboratory. *Medical Technology SA* 2017;31:1-6.
31. Coetzee MJ, Schall P, De Necker D, Labuschagne L, Louw L, Van der Westhuizen A, et al. Requests for Serological Tests for Systemic Lupus Erythematosus in Central South Africa follow Diagnostic Criteria. *Journal of Medical Laboratory Science & Technology* 2019;1(2):6-9.
32. Thomson J, Hofmann A, Barrett CA, Beeton A, Bellairs GRM, Boretti L, Coetzee MJ, Farmer S, Gibbs MW, Gombotz HH, Hilton C, Kassianides C, Louw VJ, Lundgre, C, Mahlangu JN, Noel CB, Rambiritch V, Schneider F, Verburgh E, Wessels P-L, Wessels P, Wise R, Shander A. on behalf of the South African Patient Blood Management Group. Patient blood management: A solution for South Africa. *S Afr Med J* 2019;109(7):471-6.
33. Bailly J, Louw S, De Koker A, et al. Guidelines for lupus anticoagulant testing in South Africa. *The Journal of Medical Laboratory Science & Technology South Africa* 2020;2(1):6-12. <http://dx.doi.org/10.36303/JMLSTSA.2020.2.1.39>
34. Coetzee MJ, Van Marle AC. Response to “Efficacy of oral iron therapy in geophagic women with iron deficiency anaemia residing in Botshabelo, South Africa”. *Journal of Laboratory Medical Technology of South Africa* 2020;2(2):114-5. <http://dx.doi.org/https://doi.org/10.36303/JMLSTSA.2020.2.2.56>
35. Budding L, Coetzee MJ, Joubert G. A follow-up audit of the completion of bone marrow specimen request forms at an academic laboratory. *Journal of Medical laboratory Technology of South Africa* 2020;2(2):96-9. <http://dx.doi.org/https://doi.org/10.36303/JMLSTSA.2020.2.2.58>
36. Mutize TT, Seedat RY, Ploos van Amstel JK, et al. The clinical and genetic features of hereditary haemorrhagic telangiectasia (HHT) in central South Africa-three novel pathogenic variants. *Mol Biol Rep* 2020;47:9967–72. <http://dx.doi.org/10.1007/s11033-020-05985-4>
37. van Marle AC, Acho P-M, Chapepe CO, et al. A retrospective file audit of preoperative anaemia in patients referred to the Universitas Academic Hospital Anaesthesiology Clinic before elective orthopaedic surgery. *South African Orthopaedic Journal* (in press).
38. Koekemoer HT, Joubert J, Nichol RJ, Joubert G, Coetzee MJ. Mental health disorders and health-related quality of life in adults with inherited bleeding disorders in central South Africa. *Haemophilia* 2022. <http://dx.doi.org/10.1111/hae.14486>

## Clinical Trials

### Principal investigator

Indication	Protocol Number	MCC Reference number	Role	Status of the trial(s)
Haemophilia	BAY 86-6150/ IMPACT 13787 / MATCHBOX	20080511	Principal Investigator (Bloemfontein)	Completed
Haemophilia	BAY 86-6150/ IMPACT 13861/TRUST	20100620	Principal Investigator (Bloemfontein)	Completed
Haemophilia	LFB-FVIIA-009-19	20201014	Principal Investigator (Bloemfontein)	Completed

### Good Clinical Practice including SAGCP 2020: FARMOVS (November 2021)

#### Subinvestigator on oncology studies include:

1. A Phase 2 Study to Determine the Activity of BMS-354825 in subjects with Chronic Phase Philadelphia Chromosome-positive Chronic Myeloid Leukaemia Who have Disease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or who are tolerant of Imatinib. Protocol No: CA 180013
2. A Randomised Multi-centre Open Label Study of BMS-354825 vs. Imatinib mesylate (Gleevec) 800mg/d in subjects with Chronic Phase Philadelphia Chromosome-positive Chronic Myeloid Leukaemia Who Have Disease that is Resistant to Imatinib at a dose at 400-600 mg/d. Protocol CA 180017
3. A Randomised two-by-two, Multi-centre, Open label Phase III study of BMS-354825 Administered Orally at a Dose of 50mg or 70mg Twice Daily or 100mg or 140mg once daily in subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukaemia who are Resistant or intolerant to Imatinib Mesylate (Gleevec). Protocol No: CA 180034
4. A randomised Two-Arm, Multi-Centre, Open-label Phase 2 Study of BMS-354825 Administered orally at a dose of 70mg daily (BID) or Once Daily (QD) in Subjects with Chronic Myeloid Leukemias (CML) in Accelerated Phase (AP) or in Myeloid (MY or Lymphoid (LY) Blast Phase (BP) or with Philadelphia Chromosome Positive Acute Lymphoblastic leukaemia (Ph+ALL) who are resistant or intolerant to Imatinib mesylate (Gleevec). Protocol No: CA 180-035
5. A randomised Open-Label Study of 400mg vs 800mg of Gleevec/Glivec (Imatinib mesylate) in patients with newly diagnosed chronic phase chronic Myelogenous leukaemia (CML-CP) using Molecular Endpoint. Protocol No; CST1571K2301.
6. A randomised, Controlled, Open-label, Multicentre, Comparison of Thalidomide Vs High-Dose Dexamethasone for the treatment of relapsed refractory Multiple Myeloma. Protocol No: THA PH INT 2005 CL 001.
7. CLBH589 B 2211 A phase II, multicentre study of oral LBH589 in patients with accelerated phase blast phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors.
8. Clinical Trial Protocol CAMN107A2303 A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).
9. Doxil/Caelix and Velcade study (Johnson & Johnson Pharmaceutical Research & Development Study ID: T9S Protocol number: DOXIL-MMY-3001.